Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
38.01
Dollar change
-0.95
Percentage change
-2.44
%
IndexRUT P/E- EPS (ttm)-4.64 Insider Own10.62% Shs Outstand59.43M Perf Week-5.87%
Market Cap2.32B Forward P/E- EPS next Y-2.43 Insider Trans-4.54% Shs Float54.50M Perf Month-2.56%
Income-273.86M PEG- EPS next Q-0.71 Inst Own102.15% Short Float19.43% Perf Quarter-22.13%
Sales91.93M P/S25.21 EPS this Y-39.24% Inst Trans23.99% Short Ratio18.45 Perf Half Y12.39%
Book/sh1.01 P/B37.63 EPS next Y45.49% ROA-90.63% Short Interest10.59M Perf Year126.65%
Cash/sh3.30 P/C11.52 EPS next 5Y-9.00% ROE-194.68% 52W Range15.50 - 52.57 Perf YTD-17.32%
Dividend Est.- P/FCF- EPS past 5Y-6.04% ROI-161.82% 52W High-27.70% Beta1.94
Dividend TTM- Quick Ratio4.20 Sales past 5Y175.40% Gross Margin87.45% 52W Low145.22% ATR (14)2.00
Dividend Ex-Date- Current Ratio4.35 EPS Y/Y TTM-37.91% Oper. Margin-295.57% RSI (14)43.09 Volatility4.48% 4.99%
Employees226 Debt/Eq1.76 Sales Y/Y TTM173.52% Profit Margin-297.91% Recom1.22 Target Price57.22
Option/ShortYes / Yes LT Debt/Eq1.75 EPS Q/Q-155.47% Payout- Rel Volume0.56 Prev Close38.96
Sales Surprise-3.45% EPS Surprise0.27% Sales Q/Q126.41% EarningsMay 07 BMO Avg Volume574.09K Price38.01
SMA20-4.61% SMA50-5.42% SMA2007.03% Trades Volume323,778 Change-2.44%
Date Action Analyst Rating Change Price Target Change
May-08-24Downgrade BofA Securities Buy → Neutral $49 → $42
Dec-19-23Upgrade Morgan Stanley Equal-Weight → Overweight $29 → $55
Aug-01-23Upgrade BofA Securities Neutral → Buy $22 → $27
Jan-18-23Resumed Canaccord Genuity Buy $52
Aug-08-22Upgrade Goldman Neutral → Buy $28
Aug-05-22Upgrade BofA Securities Underperform → Neutral $8 → $20
Jun-17-22Reiterated Needham Buy $40 → $25
Mar-02-22Resumed Stifel Buy $23
Feb-17-22Upgrade Ladenburg Thalmann Neutral → Buy $15
Dec-08-21Initiated Wells Fargo Overweight $30
May-09-24 04:01PM
May-08-24 10:51AM
03:06AM
May-07-24 10:34PM
02:52PM
08:58AM Loading…
08:58AM
08:36AM
08:15AM
07:00AM
May-06-24 08:00AM
Apr-30-24 10:01AM
Apr-29-24 06:30PM
Apr-28-24 09:20AM
Apr-24-24 04:01PM
Apr-16-24 04:01PM
08:00AM Loading…
Apr-01-24 08:00AM
Mar-25-24 08:00AM
Mar-22-24 07:01PM
Mar-20-24 01:49AM
01:49AM
01:49AM
Mar-11-24 04:01PM
Mar-06-24 04:01PM
Feb-23-24 12:04PM
Feb-22-24 10:19PM
08:10AM
07:35AM
07:01AM
07:00AM
Feb-16-24 03:00AM
10:00AM Loading…
Feb-15-24 10:00AM
Feb-14-24 02:30AM
Feb-13-24 03:04PM
Feb-08-24 04:01PM
Feb-07-24 08:00AM
Jan-31-24 08:00AM
Jan-12-24 04:01PM
Jan-04-24 07:00AM
06:58AM
Dec-30-23 11:01AM
Dec-15-23 04:01PM
Dec-13-23 07:00AM
Dec-08-23 05:05AM
Dec-06-23 07:00AM
Nov-17-23 09:03AM
Nov-13-23 04:01PM
Nov-07-23 08:25AM
08:00AM
07:00AM
Nov-02-23 08:00AM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-25-23 08:00AM
Oct-19-23 08:45AM
Oct-17-23 04:01PM
Oct-13-23 04:01PM
Oct-12-23 09:55AM
Oct-10-23 08:00AM
Sep-22-23 08:00AM
Sep-19-23 08:01AM
Sep-08-23 05:01PM
04:01PM
07:59AM
Sep-06-23 07:59AM
Aug-28-23 08:00AM
Aug-07-23 08:00AM
Aug-04-23 04:01PM
Aug-03-23 06:07AM
Aug-01-23 08:35AM
07:00AM
Jul-19-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 06:00AM
Jul-14-23 04:40PM
Jul-13-23 04:01PM
Jun-29-23 12:45PM
Jun-17-23 02:01PM
Jun-07-23 08:00AM
Jun-06-23 04:01PM
Jun-05-23 08:46AM
May-22-23 08:00AM
May-09-23 08:11AM
May-08-23 08:00AM
May-05-23 04:01PM
May-04-23 10:05AM
May-02-23 08:45AM
07:00AM
Apr-26-23 10:02AM
Apr-25-23 10:01AM
Apr-24-23 07:00AM
Apr-18-23 08:00AM
Apr-12-23 07:23AM
Apr-10-23 08:00AM
Apr-06-23 04:01PM
Mar-27-23 08:00AM
Mar-08-23 10:02PM
Mar-06-23 04:01PM
Mar-02-23 09:20PM
05:32AM
Mar-01-23 08:25AM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shulman JosephChief Technical OfficerMay 09 '24Option Exercise6.803,98427,0914,014May 13 04:21 PM
Shulman JosephChief Technical OfficerMay 09 '24Sale38.473,984153,25930May 13 04:21 PM
German Christopher PaulCorporate Controller & CAOApr 02 '24Sale41.7636815,368795Apr 03 08:00 PM
Shulman JosephChief Technical OfficerMar 21 '24Sale40.3418,235735,60030Mar 22 04:55 PM
Lee Jennifer KaydenEVP, Head of North AmericaMar 20 '24Sale38.7718,235707,0056,852Mar 22 04:16 PM
Meeker David PPresident and CEOMar 19 '24Sale39.2245,4941,784,275174,605Mar 19 08:54 PM
Mazabraud YannEVP, Head of InternationalMar 19 '24Sale39.2216,000627,52024,495Mar 19 08:53 PM
Smith Hunter CChief Financial OfficerMar 19 '24Sale39.2215,515608,49897,939Mar 19 08:57 PM
Shulman JosephChief Technical OfficerMar 19 '24Sale39.2215,515608,49818,265Mar 19 08:56 PM
Lee Jennifer KaydenEVP, Head of North AmericaMar 19 '24Sale39.2215,515608,49825,087Mar 19 08:52 PM
Cramer Pamela J.Chief Human Resources OfficerMar 19 '24Sale39.2215,515608,49830,005Mar 19 08:50 PM
Shulman JosephChief Technical OfficerFeb 14 '24Sale50.011,08954,46130Feb 15 06:14 PM
Shulman JosephChief Technical OfficerFeb 13 '24Sale50.001,86593,2501,119Feb 15 06:14 PM
Mazabraud YannEVP, Head of InternationalFeb 13 '24Sale49.8495747,6976,745Feb 13 08:49 PM
Smith Hunter CChief Financial OfficerFeb 13 '24Sale49.8270935,32279,704Feb 13 08:50 PM
Lee Jennifer KaydenEVP, Head of North AmericaFeb 13 '24Sale49.8361530,6456,852Feb 13 08:47 PM
Shulman JosephChief Technical OfficerFeb 13 '24Sale49.8447323,5742,984Feb 13 08:46 PM
Mazabraud YannEVP, Head of InternationalFeb 12 '24Sale51.381,59481,9007,702Feb 13 08:49 PM
Smith Hunter CChief Financial OfficerFeb 12 '24Sale51.381,20962,11880,413Feb 13 08:50 PM
Lee Jennifer KaydenEVP, Head of North AmericaFeb 12 '24Sale51.381,02352,5627,467Feb 13 08:47 PM
Shulman JosephChief Technical OfficerFeb 12 '24Sale51.3879140,6423,457Feb 13 08:46 PM
Cramer Pamela J.Chief Human Resources OfficerFeb 12 '24Sale51.3869635,76011,770Feb 13 08:45 PM
Shulman JosephChief Technical OfficerFeb 09 '24Option Exercise21.3869,1901,479,28274,460Feb 13 08:46 PM
Shulman JosephChief Technical OfficerFeb 09 '24Sale50.3871,7743,615,9822,686Feb 13 08:46 PM
Meeker David PPresident and CEOFeb 01 '24Sale45.064,361196,507121,099Feb 05 06:53 PM
Smith Hunter CChief Financial OfficerFeb 01 '24Sale45.061,61672,81775,215Feb 05 06:54 PM
Lee Jennifer KaydenEVP, Head of North AmericaFeb 01 '24Sale45.061,49267,2303,021Feb 05 06:55 PM
Shulman JosephChief Technical OfficerFeb 01 '24Sale45.061,32459,6592,614Feb 05 06:54 PM
Cramer Pamela J.Chief Human Resources OfficerFeb 01 '24Sale45.0694642,62710,122Feb 05 06:53 PM
Shulman JosephChief Technical OfficerDec 28 '23Option Exercise21.386,800145,3847,926Dec 29 04:30 PM
Shulman JosephChief Technical OfficerDec 28 '23Sale50.007,926396,3180Dec 29 04:30 PM
Shulman JosephChief Technical OfficerDec 27 '23Option Exercise21.382,40051,3126,141Dec 29 04:30 PM
Shulman JosephChief Technical OfficerDec 27 '23Sale50.015,015250,7961,126Dec 29 04:30 PM
Smith Hunter CChief Financial OfficerDec 06 '23Option Exercise6.8820,000137,60081,406Dec 07 04:16 PM
Smith Hunter CChief Financial OfficerDec 06 '23Sale40.0020,000800,00061,406Dec 07 04:16 PM
Smith Hunter CChief Financial OfficerDec 05 '23Option Exercise6.887,02648,33968,432Dec 07 04:16 PM
Smith Hunter CChief Financial OfficerDec 05 '23Sale35.067,026246,36061,406Dec 07 04:16 PM
Smith Hunter CChief Financial OfficerNov 24 '23Option Exercise6.8810,97475,50172,380Nov 28 04:05 PM
Smith Hunter CChief Financial OfficerNov 24 '23Sale35.0210,974384,33661,406Nov 28 04:05 PM
Shulman JosephChief Technical OfficerNov 14 '23Option Exercise6.8027,890189,65231,631Nov 16 04:05 PM
Smith Hunter CChief Financial OfficerNov 14 '23Option Exercise6.8812,00082,56073,406Nov 16 04:05 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 14 '23Option Exercise6.8012,03081,80413,677Nov 16 04:05 PM
Shulman JosephChief Technical OfficerNov 14 '23Sale32.0727,890894,3293,741Nov 16 04:05 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 14 '23Sale32.0113,677437,8190Nov 16 04:05 PM
Smith Hunter CChief Financial OfficerNov 14 '23Sale30.3812,000364,57361,406Nov 16 04:05 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 09 '23Option Exercise6.803,43823,3785,085Nov 13 05:44 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 09 '23Sale27.693,43895,1831,647Nov 13 05:44 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 08 '23Option Exercise6.805,71238,8427,359Nov 13 05:44 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 08 '23Sale28.905,712165,1041,647Nov 13 05:44 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 03 '23Option Exercise6.80805441,727Nov 07 06:17 PM
Lee Jennifer KaydenEVP, Head of North AmericaNov 03 '23Sale28.00802,2401,647Nov 07 06:17 PM
Lee Jennifer KaydenEVP, Head of North AmericaSep 05 '23Option Exercise6.804,51930,7297,813Sep 07 05:48 PM
Lee Jennifer KaydenEVP, Head of North AmericaSep 05 '23Sale28.056,166172,9581,647Sep 07 05:48 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 09 '23Option Exercise6.801,71811,6825,012Aug 09 04:30 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 09 '23Sale24.661,71842,3663,294Aug 09 04:30 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 07 '23Option Exercise6.808,59158,41914,517Aug 09 04:30 PM
Lee Jennifer KaydenEVP, Head of North AmericaAug 07 '23Sale24.1811,223271,3473,294Aug 09 04:30 PM
Cramer Pamela J.Chief Human Resources OfficerJul 26 '23Sale17.6493016,4058,418Jul 28 09:01 PM
Smith Hunter CChief Financial OfficerJun 16 '23Option Exercise6.882,00013,76061,406Jun 21 04:05 PM